Skip to content

Internet Explorer is no longer supported by this website.

For optimal browsing we recommend using Chrome, Firefox or Safari.
Heart icon (animated) heart icon (static)
Explore more Johnson & Johnson sites:
Page logo

Johnson & Johnson Announces it has Ended Discussions with Actelion
Johnson & Johnson Announces it has Ended Discussions with Actelion

NEW BRUNSWICK, N.J. – Dec. 13, 2016 – Johnson & Johnson (NYSE:JNJ) today confirmed it has ended discussions with Actelion Pharmaceuticals Ltd. (SIX: ATLN) regarding a potential transaction. Johnson & Johnson was not able to reach an agreement that it believed would create adequate value for its shareholders.

About Johnson & Johnson
Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 126,900 employees at more than 250 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

This communication contains “forward-looking statements” as defined in the U.S. Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: the possibility that a potential transaction involving Actelion will not be entered into or completed; if a transaction is entered into, the terms and conditions of any such transaction; and whether the potential benefits of any transaction would be realized. In addition, if and when any transaction is consummated, there will be risks and uncertainties related to the ability of the Johnson & Johnson Family of Companies to successfully integrate the products and employees of Actelion, as well as the ability to ensure continued performance or market growth of its products. A further list and description of the risks, uncertainties and other factors related to the Johnson & Johnson Family of Companies can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 3, 2016, including in Exhibit 99 thereto, and Johnson & Johnson’s subsequent filings. Copies of these filings are available online at,, or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward looking statement as a result of new information or future events or developments.

This communication does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer, to purchase or subscribe for any registered shares in Actelion, or Actelion's ADSs, nor shall it form the basis of, or be relied on in connection with, any contract there for. There are no assurances that a transaction will be reached or on what terms.


Press Contacts:
Ernie Knewitz
+1 (917) 697-2318

Amy Jo Meyer
+1 (908) 616-6250

Investor Contacts:
Joseph Wolk
+1 (732) 524-1142

Back to top
You are now leaving The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.